|
|
FDA's Psychedelic Reckoning | By Ben Comer, Chief Editor, Life Science Leader | Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits of FDA breakthrough therapy designation, and talks about why RFK Jr. as HHS Secretary could be a win for psychedelic drug developers. |
|
|
|
Companies To Watch: Terns Pharmaceuticals | By Ben Comer, Chief Editor, Life Science Leader | Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules. |
|
|
Where Are They Now? Teva Pharmaceuticals | By Ben Comer, Chief Editor, Life Science Leader | Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
